More than 480 Public Health Professionals Urge the FDA to Make Oral Contraceptives Readily Available
September 8, 2021
Dear Acting Commissioner Janet Woodcock:
We write as public health professionals, scientists, social justice advocates, business leaders, and members of civil society to urge the Food and Drug Administration (FDA) to prioritize the completion of the review process to make already common and safe formulations of oral contraceptives available over-the-counter (OTC). The evidence of the benefits of OTC availability is strong, and the public health and medical community urges the FDA to follow the science and approve an OTC oral contraceptive.
The FDA’s mandate to protect public health by ensuring the safety, efficacy and security of human drugs is critical. In the case of OTC medications, the FDA’s Center for Drug Evaluation and Research (CDER) evaluates if a drug’s benefits outweigh the risks, assures proper labelling, and assesses if OTC drugs are safe and effective for the general public without seeking treatment by a health professional. At least two pharmaceutical companies are currently in discussions with the FDA about applications to switch existing formulations to OTC status.
They have a strong, proven safety record after 60 years in the marketplace, and are widely available OTC outside of the U.S. Studies of oral contraceptives demonstrate a strong safety profile that compares favorably — and in some cases, it could be argued, better — to many medications already available OTC in the U.S. Research also shows that women can understand how to properly take oral contraceptives and screen for potential risks on their own, just as they do for pain medications, allergy medications, and even the cold medications they give their children.
Leading U.S. medical associations endorse the availability of an OTC oral contraceptive. They include the American Academy of Family Physicians and the American College of Obstetricians and Gynecologists (ACOG) Committee on Gynecologic Practice; the latter supports an OTC oral contraceptive “without age restrictions.” Their positions align with the WHO’s Consolidated Guideline on Self-Care Interventions for Health, and its recommendation that governments expand availability of contraceptive methods through places other than healthcare facilities, “with or without prescription.” More than 100 organizations, including 19 health care provider professional associations, have indicated their support of OTC access to oral contraceptives by signing on to the Oral Contraceptives OTC Working Group’s Statement of Purpose.
The Centers for Disease Control and Prevention (CDC) identified family planning as one of the 10 great public health achievements of the 20th century. A new CDC analysis shows that nearly a third of women of child-bearing age in the U.S. did not always use contraceptives during sexual encounters, and it was often due to gaps in access to effective birth control. Access to contraception is critical for people to exercise their rights to bodily autonomy and sexual and reproductive health. Correct and consistent contraceptive use dramatically reduces unintended and teen pregnancy and can help to improve health and social outcomes. A series of studies by the CDC, Guttmacher Institute, and Columbia University have demonstrated that teen pregnancy rates in the U.S. have declined dramatically since 1991, primarily because of improved contraceptive use. Still, nearly half of all pregnancies in the U.S. are unintended, with the highest rates among adolescents and young adults, underserved racial and ethnic groups, and women with lower income and education levels. Unintended pregnancy resulting from unmet contraception needs increases the risk for negative maternal and infant outcomes and creates a significant socioeconomic burden to families, health systems, and society.
A vast body of scientific evidence from more than three decades supports that women and families have better health and quality of life when contraception is made more easily accessible. In recent years, the practice of providing more oral contraceptive packs at a time to women has been shown to be associated with increased continuation of pill use, and decreases in pregnancy test use, pregnancies, and cost per client.
OTC access to oral contraceptives is critical for people of all demographic groups, including adolescents and young adults. Requiring a prescription for oral contraceptives is a significant obstacle for young people to access the care that they need and want. Young people should have the resources they need to take care of their health and plan their futures, including access to all current and any future FDA-approved OTC birth control pills. Research shows that there is no scientific basis for imposing an age restriction on birth control pills available over the counter — oral contraceptives are safe and highly effective for adolescents and contraindications are rarer among this age group compared to adult women. Research also shows that increasing access to birth control does not lead to more frequent sexual activity. Furthermore, experts on adolescent health support OTC access to birth control pills including the American Academy of Pediatrics, American Medical Association, and the Society for Adolescent Health and Medicine. Ensuring young people have equal access to OTC birth control pills would not only give them more options to prevent unintended pregnancy, but also greater control over their sexual and reproductive health and lives.
Increased access to effective and preferred contraceptive methods is especially critical in the wake of the COVID-19 pandemic. National survey data from 2020 show that one in three women of reproductive age in the U.S. had to delay or cancel a reproductive health visit or had trouble accessing family planning services and methods because of the pandemic; 27 percent of women worry more than before about affording or obtaining contraceptives. These negative impacts adversely affected people at greatest risk for reduced access to quality timely care, effective methods, and worse outcomes: Black, Indigenous, Latinx, AAPI, and other people of color, as well as LGBTQI, gender-expansive and gender non-binary folks, and people working to make ends meet.
Evidence-based advocacy and policy efforts including those from professional medical and scientific groups, those most likely to use OTC oral contraceptives, and the public at large support making oral contraceptives available over the counter: 70% of reproductive-aged women agree that policy-makers and regulatory bodies should ensure oral contraceptives be made available for over-the-counter access.
The FDA has a unique opportunity to champion an imperative advancement in sexual and reproductive health and well-being at a critical time, coming on the heels of the detrimental impact of the pandemic. We urge the agency to prioritize following the evidence and medical consensus and move forward with this long overdue initiative.
Terry McGovern, JD, Harriett and Robert H. Heilbrunn Professor and Chair, Heilbrunn Department of Population and Family Health; Director, Global Health Justice and Governance Program, Columbia University Mailman School of Public Health
Linda P. Fried, MD, MPH, Dean and DeLamar Professor of Public Health; Senior Vice President, Columbia University Medical Center; Professor of Epidemiology and Medicine, Columbia University Mailman School of Public Health
James W. Curran, MD, MPH, Dean, Rollins School of Public Health, Emory University
John Finnegan Jr., PhD, Professor & Dean, School of Public Health, University of Minnesota
Sandro Galea, MD, DrPH, Dean and Robert A Knox Professor, School of Public Health, Boston University
Wayne H. Giles, MD, MS, Dean and Professor, School of Public Health, University of Illinois at Chicago
Lynn R. Goldman, MD, MPH, MS, Michael and Lori Milken Dean of Public Health; Professor, Environmental and Occupational Health, Milken Institute School of Public Health, The George Washington University
Michael C. Lu, MD, MS, MPH, Dean, University of California, Berkeley School of Public Health
Edith Parker, MPH, DrPH, Professor and Dean, University of Iowa College of Public Health
Sten H. Vermund, MD, PhD, Anna M.R. Lauder Professor and Dean, Yale School of Public Health
Oral Contraceptives (OCs) Over-the-Counter (OTC) Working Group, housed at Ibis Reproductive Health
Cecile Richards, Cofounder, Supermajority
Lynn B Barclay, President and CEO, American Sexual Health Association
Kelly Cleland, MPA, MPH, Executive Director, American Society for Emergency Contraception
Clare Coleman, President & CEO, National Family Planning & Reproductive Health Association
Amanda Dennis, Executive Director, Society of Family Planning
Heather L. Maurer, MA, CAE, Chief Executive Officer, National Association for Nurse Practitioners in Women’s Health
Lisa Peyton-Caire, Founder, CEO & President, The Foundation for Black Women’s Wellness
Latanya Mapp Frett, President and CEO Global Fund for Women
Dazon Dixon Diallo, DHL, MPH, Founder/President, SisterLove
Lynn Roberts, Reproductive Justice Scholar Activist; SisterSong Emeritus Board Member/CUNY Graduate School of Public Health & Health Policy
Christine Harley, President/CEO, SIECUS: Sex Ed for Social Change
Rosann Mariappuram, Executive Director, Jane’s Due Process
Dr. Annabel Sowemimo, Community Sexual & Reproductive Health Doctor; Co-director/Founder, Decolonising Contraception CIC
Kai Tao, Principal and Co-Founder, IL Contraceptive Access Now- AllianceChicago
Carolyn L. Westhoff, MD, Director, Division of Family Planning and Preventive Services; Sarah Billinghurst Solomon Professor of Reproductive Health; Professor of Epidemiology and of Population & Family Health, Columbia University
Daniel Davis, MD, MPH, Former FDA medical officer in DUOG, Women’s Health Consultant
Tara Shochet, Director, Gynuity Health Projects
Jessica Pinckney, Executive Director, Access Reproductive Justice
Helen Rosenthal, NYC City Council member, District 6, Former Chair, Committee on Women and Gender Equity, New York City Council
Marge Berer, Founder Editor, Reproductive Health Matters, Coordinator, International Campaign for Women’s Right to Safe Abortion
Krista Martel, Executive Director, The Well Project
Jodi Magee, Former President/CEO, Physicians for Reproductive Health
See the full list of signatories here.